Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Reports that chloroquine and hydroxychloroquine may be effective against COVID-19 have received worldwide attention, increasing the risk of the introduction of falsified versions of these medicines. Five different types of falsified chloroquine tablets were discovered between March 31, 2020 and April 4, 2020, in Cameroon and the Democratic Republic of Congo by locally conducted thin layer chromatographic analysis. Subsequent investigation by liquid chromatography and mass spectrometry in Germany proved the absence of detectable amounts of chloroquine and the presence of undeclared active pharmaceutical ingredients, that is, paracetamol and metronidazole, in four of the samples. The fifth sample contained chloroquine, but only 22% of the declared amount. Such products represent a serious risk to patients. Their occurrence exemplifies that once medicines or vaccines against COVID-19 may be developed, falsified products will enter the market immediately, especially in low- and middle-income countries (LMICs). Timely preparations for the detection of such products are required, including the establishment of appropriate screening technologies in LMICs.

Original publication

DOI

10.4269/ajtmh.20-0363

Type

Journal

The American journal of tropical medicine and hygiene

Publication Date

07/2020

Volume

103

Pages

73 - 76

Addresses

1Pharmaceutical Institute, Eberhard Karls University Tuebingen, Tuebingen, Germany.

Keywords

Humans, Pneumonia, Viral, Coronavirus Infections, Chloroquine, Chromatography, High Pressure Liquid, Chromatography, Thin Layer, Cameroon, Democratic Republic of the Congo, Mass Spectrometry, Counterfeit Drugs, Pandemics, Betacoronavirus, COVID-19, SARS-CoV-2